Loss of heterozygosity (LOH) for a specific chromosome region may indicate the presence of a tumour suppressor gene (TSG). Studies on tumour LOH have therefore been helpful to identify many TSGs (Bièche and Lidereau, 1995) . High incidences of LOH of the 11q22-qter chromosome region have been seen in breast cancer (Hampton et al, 1994; Gudmundsson et al, 1995; Winqvist et al, 1995; Kerangueven et al, 1997; Laake et al, 1997) and also in several other human malignancies (Herbst et al, 1995; Rasio et al, 1995; Gabra et al, 1996; Hui et al, 1996) . In addition, it has been shown that chromosome 11 can suppress tumorigenicity when transferred to breast cancer (Negrini et al, 1994; Phillips et al, 1996) and melanoma cell lines (Robertson et al, 1996) .
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The distal half of chromosome 11q contains several genes indicated to be involved in tumorigenesis; e.g. ATM (the ataxia telangiectasia disorder gene at 11q23.1), DDX10 (a putative RNA helicase gene at 11q23.1), MLL1 (a gene at 11q23 frequently rearranged in acute leukaemia), LOH11CR2A (a potential tumour suppressor gene at 11q23) and CHEK1 (a gene at 11q24 encoding a protein kinase required for the DNA damage checkpoint function) (Ziemin-van der Poel et al, 1991; Savitsky et al, 1995 Savitsky et al, , 1996 Furnari et al, 1997; Monaco et al, 1997; Sanchez et al, 1997) .
LOH at 11q23 has been reported in association with poor postmetastatic survival in breast cancer (Winqvist et al, 1995) . The crucial region of LOH seemed to map between loci D11S35 (11q22) and APOC3 (apolipoprotein C-3 at 11q23) (Hampton et al, 1994) , in a chromosomal segment of less than 17 Mb (Arai et al, 1996) . In the initial study of a Finnish breast cancer cohort, APOC3 appeared to be the most suitable marker for more careful examinations of the clinical effects of LOH of the 11q23 chromosomal region. Therefore, in the present European multicentrestudy, we analysed tumour and normal tissue pairs of 766 primary breast cancer patients from 11 countries to investigate the association between LOH at the APOC3 locus and clinical variables in greater detail.
MATERIALS AND METHODS
Altogether 766 primary tumour and normal tissue pairs from breast cancer patients were collected for the LOH analysis. The European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables studied patient material was collected from 15 different research centres, representing 11 European countries (Table 1) . Clinical characteristics are summarized in Tables 1 and 2 . The patients studied were diagnosed with primary breast cancer between 1978 and 1996. The mean age of disease onset was 57 years (range 27-95). The mean follow-up time of those patients still alive was 57 months (range . Information about the family history of breast/ovarian cancer (in two or three first-degree relatives) and disease bilaterality was also collected. Tumours were classified according to size (< 2 cm, 2-5 cm or > 5 cm in diameter), histology, histoprognostic grade, and oestrogen receptor and progesterone receptor status. In addition, information about node and metastasis status at the time of diagnosis and possible adjuvant cancer therapy was obtained. Twenty-eight (4.7%) of the patients presented with metastatic disease at the time of diagnosis, while an additional 203 patients displayed local and/or distal tumour recurrence/metastasis during the clinical follow-up time. All cases from Sweden and the Netherlands were selected according to a metastatic disease course during the clinical follow-up time.
DNA from tumour tissue (fresh or paraffin-embedded) and corresponding normal tissue (blood, fresh or paraffin-embedded tissue) was extracted using standard phenol-chloroform protocols. Only a minority of the tissue material used was from paraffinembedded tissues (2%, (17/766), all cases from Slovenia). In these cases DNA was extracted using the methods described by Sarkar (1995) . The LOH analysis using the highly informative mononucleotide repeat microsatellite marker APOC3 (Bhattacharya et al, 1991) was performed either in Oulu or in the research centre from where the tissue material was collected. Polymerase chain reaction (PCR) was performed mainly as described previously (Bhattacharya et al, 1991) , with some slight modifications, e.g. alternatively using radioactive or non-radioactive PCR methods. In the radioactive protocols we used either direct incorporation of [α-32 ]-dCTP or [ 32 P]-end-labelled PCR primers. Two different non-radioactive PCR protocols were used. One utilized silver staining to visualize the PCR products after electrophoresis. The other method used fluorescent-labelled PCR primers and an automated DNA sequencer for fragment analysis (Pharmacia, ALF; Perkin-Elmer Applied Biosystems, model 373A). In all cases, the PCR products were resolved by electrophoresis on 6-7% denaturing polyacrylamide gels. The evaluation of LOH status was performed in the radioactive method by comparing the normal and tumour tissue allele intensity ratios of the autoradiograms. Each case was evaluated by at least two independent viewers who compared their observations. In the fluorescent-labelled microsatellite analysis the data were analysed with appropriate software (Pharmacia, Fragment Manager FM1.1; Perkin Elmer Applied Biosystems, Gene Scan) by comparing normal and tumour tissue allele peak sizes, heights and area ratios. In both methods, intensity or signal ratio differences of at least 25% (depending on the proportion of tumour cells or method used) were considered sufficient for LOH assignment. The Fisher's two-tailed exact test, the Mann-Whitney test, the Pearson test and the stepwise logistic regression analysis methods were used for the statistical evaluation of associations between LOH at 11q23 and clinical findings. Survival curves calculated by Kaplan-Meier estimations were compared according to the logrank test. P-values below 0.01 were considered significant. Only subpopulations with more than 40 breast cancer cases were analysed independently.
RESULTS AND DISCUSSION
The results obtained from LOH analysis of the 11q23 subregion at APOC3 are summarized in Tables 2 and 3 . The APOC3 marker was informative for determining LOH status in 78% of the studied cases. LOH was observed in 42% of the tumours. The LOH frequencies of the larger unselected subpopulations (with at least 40 patients) varied from 32% to 56%. In addition to the studied cohort, differencies seen in the LOH incidences could also be due to the analysis methods used. The LOH frequency was 47% in the patients with recurrent/metastatic disease (data not shown). Interestingly, primary tumours of the two small populations from Sweden and The Netherlands that had been selected for the presence of a metastatic disease course displayed the highest LOH frequencies (64% and 89% respectively).
According to the statistical analysis, no strong association was found between primary tumour LOH at APOC3 and any of the studied clinical variables (tumour size, node or metastasis status, histoprognostic grade, histology type, oestrogen or progesterone status, adjuvant therapy, bilaterality vs unilaterality, and family history of cancer). Correlation was seen between occurrence of LOH and disease onset at a higher age (P = 0.014). This could reflect the observation that the frequency of LOH was 43% (122/282) for the sporadic cases, but only 31% (22/70) for the cases with a positive family history of cancer, known usually to have earlier onset of the disease. No association was seen between LOH and cancer-specific survival time (P = 0.146) or survival after diagnosis of recurrence/metastasis (P = 0.987).
Although most of the studied cohorts represent cases from a certain time period, they seemed to be clinically heterogeneous. Nevertheless, we analysed separately all subpopulations consisting of at least 40 patients. Only a slight correlation was observed between LOH at APOC3 and a positive oestrogen status in the Germany II cohort (P = 0.029), a greater tumour size and a more advanced tumour grade in the France II cohort (P = 0.026 and P= 0.024 respectively), and a more advanced tumour grade in the sporadic cases of the Norwegian cohort (P = 0.025). We could not detect a significant association between LOH for APOC3 and cancer-specific survival times or survival after recurrence/metastasis in any of the studied subpopulations. Only in the Finnish cohort was a slight correlation between LOH and reduced survival times after disease recurrence/metastasis seen (P = 0.026) ( Figure  1) . However, the clinical association was found to be much weaker than in the initial analysis of the same cohort (P = 0.0004; Winqvist et al, 1995) . The difference could be explained by the fact that in the current investigation, due to the longer follow-up time, a greater number of patients showed relapse. In the previous analysis, the follow-up time was approximately 3-5 years and, altogether, 28 patients displayed a metastatic disease. In this study, five more cases showed a metastatic disease course during the updated follow-up time (mean > 6 years, range 5-117 months). Interestingly, due to the prolonged follow-up time, the correlation between LOH at 11q23 and shortened post-metastatic survival time was not as strong as had been seen previously, suggesting that in the Finnish cohort the adverse effect on survival is mainly limited to the first 2-3 years after relapse.
The results presented here make it unlikely that the putative survival factor gene on 11q23 would be situated very close to the subregion containing the APOC3 gene. As our previous studies have indicated that the crucial region of LOH seems to be located between the D11S35 and APOC3 loci (Hampton et al, 1994;  Figure 1 Kaplan-Meier estimates for survival curves of breast cancer patients after diagnosis of recurrence/metastasis in the Finnish cohort. The patients with LOH at APOC3 in their tumours showed slightly reduced survival times (P = 0.026, log-rank test) Winqvist et al, 1995) , it is possible that the survival factor gene could be at a more proximal location. Interestingly, one additional subregion exhibiting LOH on chromosome 11q23 has been mapped closer to the DDX10 and ATM genes (Laake et al, 1997; Hui et al, 1996) . The involovement of this subregion was confirmed by our parallel study on LOH of 11q23. Possible additional targets of LOH on chromosome 11q could include the CHEK1 and LOH11CR2A genes (Furnari et al, 1997; Sanchez et al, 1997; Monaco et al, 1997) . However, LOH11CR2A gene mutations have not so far been detected in breast, ovarian or lung tumours (Monaco et al, 1997) . As chromosome 11q seems to harbour multiple genes important for tumour development, it is likely that the size and number of deleted chromosomal segments could be important for determining their clinical effects.
In conclusion, LOH of 11q23 at APOC3 is a frequent finding in primary breast tumours, and it is even more common in the tumours of patients developing a more advanced disease. However, LOH was not seen to be strongly associated with any of the studied clinical variables, suggesting that the putative survival factor gene on 11q23 is not located in the immediate vicinity of the APOC3 locus, but more likely further proximal towards the chromosomal subregion harbouring the DDX10 and ATM genes.
